Bambusa Therapeutics Presents Positive Preliminary Multiple Ascending Dose Phase 1 Data for BBT002 at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026
PR Newswire
BOSTON, June 15, 2026
- BBT002 is a next-generation, long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-5 - - BBT002 demonstrated rapid, deep, and sustained biomarker effects through at least 8 weeks following multiple doses, consistent with the SAD data, with a ~29.4-day half-life supporting extended dosing intervals -- Topline data from ongoing proof-of-concept trials evaluating BBT002 in patients with COPD and CRSwNP anticipated by year-end 2026 and first half of 2027, respectively -BOSTON, June 15, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa Therapeutics), a clinical-stage biotechnology company advancing next-generation, long-acting bispecific antibodies for immunology and inflammation, today announced positive preliminary data from the multiple ascending dose (MAD) cohorts of its Phase 1 trial evaluating BBT002 in healthy volunteers. The results were reviewed in an oral presentation at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026, taking place from June 12-15, 2026 in Istanbul, Turkey.
